Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

By P. Ridker, Brendan M. Everett, A. Pradhan, Jean G Macfadyen, Daniel H. Solomon, Elaine Zaharris, Virak Mam, Ahmed A Hasan, Y. Rosenberg, E. Iturriaga and 16 more. New England Journal of Medicine, 2018

1,101 citations recorded by the source corpus.

BACKGROUND Inflammation is causally related to atherothrombosis. Treatment with canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin‐1β, resulted in a lower rate of cardiovascular events than placebo in a previous randomized trial. We sought to determine whether an alternative approach to inflammation inhibition with low‐dose methotrexate might provide similar benefit. METHODS We conducted a randomized, double‐blind trial of low‐dose methotrexate (at a target dose of 15 to 20 mg weekly) or matching placebo in 4786 patients with previous myocardial infarction or multivessel coronary disease who additionally had either type 2 diabetes or the metabolic syndrome. All participants received 1 mg of folate daily. The primary end point at the onset of the trial was a composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Near the conclusion of the trial, but before unblinding, hospitalization for unstable angina that led to urgent revascularization was added to the primary end point. RESULTS The trial was stopped after a median follow‐up of 2.3 years. Methotrexate did not result in lower interleukin‐1β, interleukin‐6, or C‐reactive protein levels than placebo. The final primary end point occurred in 201 patients in the methotrexate group and in 207 in the placebo group (incidence rate, 4.13 vs. 4.31 per 100 person‐years; hazard ratio, 0.96; 95% confidence interval [CI], 0.79 to 1.16). The original primary end point occurred in 170 patients in the methotrexate group and in 167 in the placebo group (incidence rate, 3.46 vs. 3.43 per 100 person‐years; hazard ratio, 1.01; 95% CI, 0.82 to 1.25). Methotrexate was associated with elevations in liver‐enzyme levels, reductions in leukocyte counts and hematocrit levels, and a higher incidence of non–basal‐cell skin cancers than placebo. CONCLUSIONS Among patients with stable atherosclerosis, low‐dose methotrexate did not reduce levels of interleukin‐1β, interleukin‐6, or C‐reactive protein and did not result in fewer cardiovascular events than placebo. (Funded by the National Heart, Lung, and Blood Institute; CIRT ClinicalTrials.gov number, NCT01594333.)

Subfields: Immunology, Molecular Biology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/48cdb71325108c04f97deadb9ed39db74bc33540

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

  1. Lina Badimon
  2. Alberico L. Catapano
  3. Rhian M. Touyz

In Molecular Biology

  1. I. Graham
  2. Alberico L. Catapano
  3. Rhian M. Touyz
  4. Ulrich Laufs

In Rheumatology

  1. I. Graham

Citations in the corpus